Monday, June 5, 2023
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for infectious disease clinicians, family medicine/primary care clinicians, internists, gastroenterologists, public health and prevention officials, nurses, nurse practitioners, pharmacists, physician assistants, and other members of the healthcare team involved in hepatitis B testing in adults.
The goal of this activity is for members of the healthcare team to be better able to describe updated guidelines from the Centers for Disease Control and Prevention (CDC) for hepatitis B virus (HBV) testing of adults, according to an update of their 2008 recommendations for risk-based testing and management of persons with chronic HBV infection in the United States.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-125-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 4/14/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 4/14/2023
Valid for credit through: 4/14/2024
processing....
Persons with chronic hepatitis B virus (HBV) infection are at greater risk for liver cancer and cirrhosis and are 70% to 85% more likely to die prematurely than the general population. Of an estimated 580,000 to 2.4 million persons living with HBV infection in the United States, two-thirds may be unaware of their infection.
Chronic HBV infection disproportionately affects persons born outside the United States, as non--US–born persons account for 14% of the general US population but 69% of persons living with chronic HBV infection. Treatment is not considered curative, but antiviral treatment, monitoring, and liver cancer surveillance can lower morbidity and mortality.
Adults should be tested for HBV at least once in their lifetime, according to updated guidelines from the Centers for Disease Control and Prevention (CDC).
This is the first update to HBV screening guidelines since 2008, the agency said.
"Risk-based testing alone has not identified most persons living with chronic HBV infection and is considered inefficient for providers to implement,” the authors wrote in the new guidance, published in the CDC's Morbidity and Mortality Weekly Report. "Universal screening of adults for HBV infection is cost-effective compared with risk-based screening and averts liver disease and death. Although a curative treatment is not yet available, early diagnosis and treatment of chronic HBV infections reduces the risk for cirrhosis, liver cancer, and death.”
An estimated 580,000 to 2.4 million individuals are living with HBV infection in the United States, and two-thirds may be unaware they are infected, the agency said.
The virus spreads through contact with blood, semen, and other body fluids of an infected person.
The guidance now recommends using the triple panel (hepatitis B surface antigen [HBsAg], anti-hepatitis B [HB], total anti-hepatitis B core [antigen] [HBc]) for initial screening.
"It can help identify persons who have an active HBV infection and could be linked to care; have [a] resolved infection and might be susceptible to reactivation (eg, immunosuppressed persons); are susceptible and need vaccination; or are vaccinated,” the authors wrote.
Pregnant women should be screened ideally in the first trimester of each pregnancy, regardless of vaccination status or testing history. Pregnant women who have already received timely triple-panel screening for HBV and who have no new HBV exposures only need HBsAg screening, the guidelines state.
The document added 3 groups at higher risk for HBV infection: persons incarcerated or formerly incarcerated, people with current or past hepatitis C virus (HCV) infection, and people with current or past sexually transmitted infections (STIs) and multiple sex partners. Persons at higher risk for HBV should be screened periodically, based on shared decision making between the provider and patient as well as individual risk and immune status.
Additional research into the optimal frequency of periodic testing is necessary, the authors said.
"Along with vaccination strategies, universal screening of adults and appropriate testing of persons at increased risk for HBV infection will improve health outcomes, reduce the prevalence of HBV infection in the United States, and advance viral hepatitis elimination goals," the authors wrote.
MMWR Recomm Rep. 2023;72:1-25.[1]
